Skip to main content
Erschienen in: Current Cardiology Reports 7/2019

01.07.2019 | Hypertension (DS Geller and DL Cohen, Section Editors)

Masked Hypertension in CKD: Increased Prevalence and Risk for Cardiovascular and Renal Events

verfasst von: Megha Babu, Paul Drawz

Erschienen in: Current Cardiology Reports | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Hypertension and chronic kidney disease (CKD) are inextricably linked. The causal nature of the relationship is bidirectional. This relationship holds when blood pressure is assessed in the clinic and outside the clinic with home and ambulatory blood pressure monitoring. Patients with CKD are more likely to have high-risk hypertension phenotypes, such as masked and sustained hypertension, and are at increased risk for cardiovascular disease. The purpose of this review is to describe the increased prevalence of masked hypertension in patients with CKD and then describe the increased risk for target organ damage and adverse clinical events associated with masked hypertension in patients with CKD.

Recent Findings

The prevalence of masked hypertension is greater in patients with CKD than that of the general population. Recent studies have demonstrated that masked hypertension is associated with increased risk for target organ damage including left ventricular hypertrophy, elevated pulse wave velocity, proteinuria, and decreased estimated glomerular filtration rate in patients with CKD. Additionally, in patients with CKD, masked hypertension is associated with increased risk for cardiovascular disease, end-stage renal disease, and all-cause mortality.

Summary

Patients with CKD are at increased risk for masked hypertension. Masked hypertension is associated with increased risk for target organ damage and adverse cardiovascular and renal outcomes in patients with CKD. Further research is necessary to better understand the pathophysiology of masked hypertension, the optimal method for diagnosing masked hypertension, and to determine whether masked hypertension is a modifiable risk factor.
Literatur
1.
Zurück zum Zitat Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55(3):441–51.PubMedCrossRef Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55(3):441–51.PubMedCrossRef
2.
Zurück zum Zitat Sarafidis PA, Li S, Chen SC, Collins AJ, Brown WW, Klag MJ, et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008;121(4):332–40.PubMedCrossRef Sarafidis PA, Li S, Chen SC, Collins AJ, Brown WW, Klag MJ, et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008;121(4):332–40.PubMedCrossRef
3.
Zurück zum Zitat Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi C, Volpe M. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens. 2014;28(2):74–9.PubMedCrossRef Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi C, Volpe M. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens. 2014;28(2):74–9.PubMedCrossRef
4.
Zurück zum Zitat Pirkle JL, Freedman BI. Hypertension and chronic kidney disease: controversies in pathogenesis and treatment. Minerva Urol Nefrol. 2013;65(1):37–50.PubMedPubMedCentral Pirkle JL, Freedman BI. Hypertension and chronic kidney disease: controversies in pathogenesis and treatment. Minerva Urol Nefrol. 2013;65(1):37–50.PubMedPubMedCentral
5.
Zurück zum Zitat Agarwal R, Andersen MJ. Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006;69(2):406–11.PubMedCrossRef Agarwal R, Andersen MJ. Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006;69(2):406–11.PubMedCrossRef
6.
Zurück zum Zitat Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52.PubMedCrossRef Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52.PubMedCrossRef
7.
Zurück zum Zitat United States Renal Data System, 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2014. http://www.usrds.org/2014/view/v1_01.aspx, accessed on September 13, 2017. In. United States Renal Data System, 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2014. http://​www.​usrds.​org/​2014/​view/​v1_​01.​aspx, accessed on September 13, 2017. In.
8.
Zurück zum Zitat Kokubo Y, Kamide K. High-normal blood pressure and the risk of cardiovascular disease. Circ J. 2009;73(8):1381–5.PubMedCrossRef Kokubo Y, Kamide K. High-normal blood pressure and the risk of cardiovascular disease. Circ J. 2009;73(8):1381–5.PubMedCrossRef
9.
Zurück zum Zitat Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005;142(5):342–51.PubMedCrossRef Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005;142(5):342–51.PubMedCrossRef
10.
Zurück zum Zitat Ku E, Gassman J, Appel LJ, Smogorzewski M, Sarnak MJ, Glidden DV, et al. BP control and long-term risk of ESRD and mortality. J Am Soc Nephrol. 2017;28(2):671–7.PubMedCrossRef Ku E, Gassman J, Appel LJ, Smogorzewski M, Sarnak MJ, Glidden DV, et al. BP control and long-term risk of ESRD and mortality. J Am Soc Nephrol. 2017;28(2):671–7.PubMedCrossRef
11.
Zurück zum Zitat Wright JT, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.PubMedCrossRef Wright JT, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.PubMedCrossRef
12.
Zurück zum Zitat Drawz PE, Pajewski NM, Bates JT, Bello NA, Cushman WC, Dwyer JP, et al. Effect of intensive versus standard clinic-based hypertension management on ambulatory blood pressure: results from the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study. Hypertension. 2017;69(1):42–50.PubMedCrossRef Drawz PE, Pajewski NM, Bates JT, Bello NA, Cushman WC, Dwyer JP, et al. Effect of intensive versus standard clinic-based hypertension management on ambulatory blood pressure: results from the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study. Hypertension. 2017;69(1):42–50.PubMedCrossRef
13.
Zurück zum Zitat Franklin SS, O’Brien E, Staessen JA. Masked hypertension: understanding its complexity. Eur Heart J. 2017;38(15):1112–8.PubMed Franklin SS, O’Brien E, Staessen JA. Masked hypertension: understanding its complexity. Eur Heart J. 2017;38(15):1112–8.PubMed
14.
15.
Zurück zum Zitat Anstey DE, Shimbo D. Masked hypertension-what lies ahead? J Hum Hypertens. 2017;31(9):545–6.PubMedCrossRef Anstey DE, Shimbo D. Masked hypertension-what lies ahead? J Hum Hypertens. 2017;31(9):545–6.PubMedCrossRef
16.
17.
Zurück zum Zitat Siu AL. Force USPST. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(10):778–86.PubMedCrossRef Siu AL. Force USPST. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(10):778–86.PubMedCrossRef
18.
Zurück zum Zitat •• Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018. 2017;71(19):e127–248 This guideline recommends out-of-office BP measurements to detect white-coat and masked hypertension in both the diagnosis and treatment of hypertension. CrossRef •• Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018. 2017;71(19):e127–248 This guideline recommends out-of-office BP measurements to detect white-coat and masked hypertension in both the diagnosis and treatment of hypertension. CrossRef
19.
Zurück zum Zitat Hänninen MR, Niiranen TJ, Puukka PJ, Kesäniemi YA, Kähönen M, Jula AM. Target organ damage and masked hypertension in the general population: the Finn-Home study. J Hypertens. 2013;31(6):1136–43.PubMedCrossRef Hänninen MR, Niiranen TJ, Puukka PJ, Kesäniemi YA, Kähönen M, Jula AM. Target organ damage and masked hypertension in the general population: the Finn-Home study. J Hypertens. 2013;31(6):1136–43.PubMedCrossRef
20.
Zurück zum Zitat Asayama K, Thijs L, Li Y, Gu YM, Hara A, Liu YP, et al. Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population. Hypertension. 2014;64(5):935–42.PubMedCrossRef Asayama K, Thijs L, Li Y, Gu YM, Hara A, Liu YP, et al. Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population. Hypertension. 2014;64(5):935–42.PubMedCrossRef
21.
Zurück zum Zitat Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA. 2004;291(11):1342–9.PubMedCrossRef Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA. 2004;291(11):1342–9.PubMedCrossRef
22.
Zurück zum Zitat Liu JE, Roman MJ, Pini R, Schwartz JE, Pickering TG, Devereux RB. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med. 1999;131(8):564–72.PubMedCrossRef Liu JE, Roman MJ, Pini R, Schwartz JE, Pickering TG, Devereux RB. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med. 1999;131(8):564–72.PubMedCrossRef
23.
Zurück zum Zitat Verberk WJ, Kessels AG, de Leeuw PW. Prevalence, causes, and consequences of masked hypertension: a meta-analysis. Am J Hypertens. 2008;21(9):969–75.PubMedCrossRef Verberk WJ, Kessels AG, de Leeuw PW. Prevalence, causes, and consequences of masked hypertension: a meta-analysis. Am J Hypertens. 2008;21(9):969–75.PubMedCrossRef
24.
Zurück zum Zitat Drawz PE, Alper AB, Anderson AH, Brecklin CS, Charleston J, Chen J, et al. Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage. Clin J Am Soc Nephrol. 2016;11(4):642–52.PubMedPubMedCentralCrossRef Drawz PE, Alper AB, Anderson AH, Brecklin CS, Charleston J, Chen J, et al. Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage. Clin J Am Soc Nephrol. 2016;11(4):642–52.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Iimuro S, Imai E, Watanabe T, Nitta K, Akizawa T, Matsuo S, et al. Clinical correlates of ambulatory BP monitoring among patients with CKD. Clin J Am Soc Nephrol. 2013;8(5):721–30.PubMedPubMedCentralCrossRef Iimuro S, Imai E, Watanabe T, Nitta K, Akizawa T, Matsuo S, et al. Clinical correlates of ambulatory BP monitoring among patients with CKD. Clin J Am Soc Nephrol. 2013;8(5):721–30.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M, et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension. 2009;53(1):20–7.PubMedCrossRef Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M, et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension. 2009;53(1):20–7.PubMedCrossRef
27.
Zurück zum Zitat Bangash F, Agarwal R. Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2009;4(3):656–64.PubMedPubMedCentralCrossRef Bangash F, Agarwal R. Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2009;4(3):656–64.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Drawz PE, Brown R, De Nicola L, et al. Variations in 24-hour BP profiles in cohorts of patients with kidney disease around the world: the I-DARE Study. Clin J Am Soc Nephrol. 2018;13(9):1348–57.PubMedCrossRefPubMedCentral Drawz PE, Brown R, De Nicola L, et al. Variations in 24-hour BP profiles in cohorts of patients with kidney disease around the world: the I-DARE Study. Clin J Am Soc Nephrol. 2018;13(9):1348–57.PubMedCrossRefPubMedCentral
29.
Zurück zum Zitat Matsui Y, Eguchi K, Ishikawa J, Hoshide S, Shimada K, Kario K. Subclinical arterial damage in untreated masked hypertensive subjects detected by home blood pressure measurement. Am J Hypertens. 2007;20(4):385–91.PubMedCrossRef Matsui Y, Eguchi K, Ishikawa J, Hoshide S, Shimada K, Kario K. Subclinical arterial damage in untreated masked hypertensive subjects detected by home blood pressure measurement. Am J Hypertens. 2007;20(4):385–91.PubMedCrossRef
30.
Zurück zum Zitat Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007;25(11):2193–8.PubMedCrossRef Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007;25(11):2193–8.PubMedCrossRef
31.
Zurück zum Zitat Tang H, Gong WY, Zhang QZ, Zhang J, Ye ZC, Peng H, et al. Prevalence, determinants, and clinical significance of masked hypertension and white-coat hypertension in patients with chronic kidney disease. Nephrology (Carlton). 2016;21(10):841–50.CrossRef Tang H, Gong WY, Zhang QZ, Zhang J, Ye ZC, Peng H, et al. Prevalence, determinants, and clinical significance of masked hypertension and white-coat hypertension in patients with chronic kidney disease. Nephrology (Carlton). 2016;21(10):841–50.CrossRef
32.
Zurück zum Zitat Kanno A, Metoki H, Kikuya M, et al. Usefulness of assessing masked and white-coat hypertension by ambulatory blood pressure monitoring for determining prevalent risk of chronic kidney disease: the Ohasama study. Hypertens Res. 2010;33(11):1192–8.PubMedCrossRef Kanno A, Metoki H, Kikuya M, et al. Usefulness of assessing masked and white-coat hypertension by ambulatory blood pressure monitoring for determining prevalent risk of chronic kidney disease: the Ohasama study. Hypertens Res. 2010;33(11):1192–8.PubMedCrossRef
33.
Zurück zum Zitat Agarwal R, Light RP. GFR, proteinuria and circadian blood pressure. Nephrol Dial Transplant. 2009;24:2400–6.PubMedCrossRef Agarwal R, Light RP. GFR, proteinuria and circadian blood pressure. Nephrol Dial Transplant. 2009;24:2400–6.PubMedCrossRef
34.
Zurück zum Zitat Agarwal R, Pappas MK. Delayed systolic blood pressure recovery following exercise as a mechanism of masked uncontrolled hypertension in chronic kidney disease. Nephrol Dial Transplant. 2017;32(10):1710–7.PubMed Agarwal R, Pappas MK. Delayed systolic blood pressure recovery following exercise as a mechanism of masked uncontrolled hypertension in chronic kidney disease. Nephrol Dial Transplant. 2017;32(10):1710–7.PubMed
35.
Zurück zum Zitat •• Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality. N Engl J Med. 2018;378(16):1509–20 This large study from Spain demonstrated increased risk for both all-cause and cardiovascular mortality in patients with masked and masked uncontrolled hypertension. PubMedCrossRef •• Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality. N Engl J Med. 2018;378(16):1509–20 This large study from Spain demonstrated increased risk for both all-cause and cardiovascular mortality in patients with masked and masked uncontrolled hypertension. PubMedCrossRef
36.
Zurück zum Zitat Mwasongwe S, Min YI, Booth JN, et al. Masked hypertension and kidney function decline: the Jackson Heart Study. J Hypertens. 2018;36(7):1524–32.PubMedPubMedCentralCrossRef Mwasongwe S, Min YI, Booth JN, et al. Masked hypertension and kidney function decline: the Jackson Heart Study. J Hypertens. 2018;36(7):1524–32.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Kushiro T, Kario K, Saito I, et al. Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease: the HONEST Study. Hypertens Res. 2017;40(1):87–95.PubMedCrossRef Kushiro T, Kario K, Saito I, et al. Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease: the HONEST Study. Hypertens Res. 2017;40(1):87–95.PubMedCrossRef
38.
Zurück zum Zitat Minutolo R, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, et al. Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study. Am J Kidney Dis. 2014;64(5):744–52.PubMedCrossRef Minutolo R, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, et al. Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study. Am J Kidney Dis. 2014;64(5):744–52.PubMedCrossRef
39.
Zurück zum Zitat Wang C, Zhang J, Li Y, Ma X, Ye Z, Peng H, et al. Masked hypertension, rather than white-coat hypertension, has a prognostic role in patients with non-dialysis chronic kidney disease. Int J Cardiol. 2017;230:33–9.PubMedCrossRef Wang C, Zhang J, Li Y, Ma X, Ye Z, Peng H, et al. Masked hypertension, rather than white-coat hypertension, has a prognostic role in patients with non-dialysis chronic kidney disease. Int J Cardiol. 2017;230:33–9.PubMedCrossRef
40.
Zurück zum Zitat Agarwal R, Andersen MJ. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006;69(7):1175–80.PubMedCrossRef Agarwal R, Andersen MJ. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006;69(7):1175–80.PubMedCrossRef
41.
Zurück zum Zitat Agarwal R, Andersen MJ. Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease. Am J Nephrol. 2006;26(5):503–10.PubMedCrossRef Agarwal R, Andersen MJ. Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease. Am J Nephrol. 2006;26(5):503–10.PubMedCrossRef
42.
Zurück zum Zitat Gabbai FB, Rahman M, Hu B, Appel LJ, Charleston J, Contreras G, et al. Relationship between ambulatory BP and clinical outcomes in patients with hypertensive CKD. Clin J Am Soc Nephrol. 2012;7(11):1770–6.PubMedPubMedCentralCrossRef Gabbai FB, Rahman M, Hu B, Appel LJ, Charleston J, Contreras G, et al. Relationship between ambulatory BP and clinical outcomes in patients with hypertensive CKD. Clin J Am Soc Nephrol. 2012;7(11):1770–6.PubMedPubMedCentralCrossRef
Metadaten
Titel
Masked Hypertension in CKD: Increased Prevalence and Risk for Cardiovascular and Renal Events
verfasst von
Megha Babu
Paul Drawz
Publikationsdatum
01.07.2019
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 7/2019
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-019-1154-4

Weitere Artikel der Ausgabe 7/2019

Current Cardiology Reports 7/2019 Zur Ausgabe

Structural Heart Disease (RJ Siegel and NC Wunderlich, Section Editors)

Aortic Regurgitation

Structural Heart Disease (RJ Siegel and NC Wunderlich, Section Editors)

Specific Anatomic Considerations for Tricuspid Interventions

Heart Failure (HJ Eisen, Section Editor)

Pulmonary Hypertension Due to Left Heart Disease: an Update

Nuclear Cardiology (V Dilsizian, Section Editor)

Diagnosis and Prognosis of Coronary Artery Disease with SPECT and PET

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

PET kann infarktgefährdete Koronararterien entdecken

04.06.2024 Koronare Herzerkrankung Nachrichten

Der Nachweis aktiver Plaques mittels 18F-Natriumfluorid-PET hilft nicht nur, infarktgefährdete Patienten, sondern auch infarktgefährdete Koronararterien zu erkennen. Von einer gezielten Behandlung vulnerabler Plaques ist man trotzdem weit entfernt.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.